Loading organizations...
Key people at Ziff Capital Partners.
Ziff Capital Partners was founded in 2015 by Dirk Ziff (Founder).
Ziff Capital Partners is a Chicago-based private investment firm specializing in direct debt and equity investments within industrial manufacturing, transportation, and construction sectors. The firm provides comprehensive capital asset monetization and financing solutions, aiding companies through transitions, distress, or start-up phases. Ziff Capital creatively structures financing, purchases and refinances debt, and acquires industrial capital assets and real property, aiming to deliver optimal liquidity and maximize recovery for clients. Their approach includes advisory services for asset disposition, leveraging key deal terms and negotiation strategies.
Benjamin Martin Ziff founded Ziff Capital in 2019, bringing a deep understanding of industrial asset finance and disposition to the firm. Prior to establishing Ziff Capital, Ziff accumulated twelve years of experience working with machinery and equipment auctioneers, liquidators, demolition firms, C&I note purchasers, and asset-based lenders. This extensive background provides the specialized insight into industrial capital asset valuations and strategic transactions that underpins Ziff Capital's tailored financial solutions.
The firm serves a diverse clientele including public and private industrial companies, financial advisors, attorneys, and various consultants involved in asset management and restructuring. Ziff Capital's vision centers on offering expeditious and customized financial strategies, acquiring unwanted property, plant, and equipment (PP&E), and taking on asset risk to provide upfront cash to clients. They aim to empower businesses with efficient capital solutions and expert guidance through complex asset-related scenarios.
Ziff Capital Partners was founded in 2015 by Dirk Ziff (Founder).
Key people at Ziff Capital Partners.
Ziff Capital Partners has 5 tracked investments across 5 companies. The latest tracked deal is $54.0M Series A in Corner Therapeutics in April 2024.